Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Tasigna Recommended for EU Approval as 1st-Line Treatment for CML
October 18, 2010
- Zibotentan Fails to Extend OS in CRPC Patients
October 18, 2010
- SANTEC Transfers CRO Business to Clio Science
October 18, 2010
- Ticagrelor Receives Positive Opinion from CHMP
October 18, 2010
- Points Should Not Be Given for Out-of-Pocket Payments for Dispensing Services: JPA
October 18, 2010
- NHI Price Listing of Generic Aricept Remains Uncertain
October 18, 2010
- Korosho Revises Package Insert for Victoza Following Report of 2 Deaths
October 18, 2010
- Linagliptin Improves HbA1c with and without SU
October 18, 2010
- ASKLEP Sets Up Subsidiary in China
October 18, 2010
- PMDA to Accept Regulatory Officials from KFDA for Training
October 18, 2010
- Early Addition of Saxagliptin Effective in Achieving Target HbA1c Levels
October 18, 2010
- Apo Plus Station Carries Out MBO
October 18, 2010
- NEW PRODUCTS
October 18, 2010
- Gov't to Create Fund to Subsidize Vaccination against HPV
October 18, 2010
- Sandoz Launches First Ramosetron Generic in Japan
October 18, 2010
- Takeda Ties Up with Envoy to Develop Schizophrenia Drugs
October 18, 2010
- Market for OTC Kampo Medicines to Grow 0.8% to ¥239.4 Bil. in 2010
October 18, 2010
- Ranbaxy Granted 180-Day Exclusivity for Generic Aricept in the US
October 18, 2010
- Asubio Pharma Starts Operation in Kobe
October 18, 2010
- 2-Week Prescription Limit Lifted for Reflex, Remeron
October 18, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…